Scholl Professor News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Scholl Professor. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Scholl Professor Today - Breaking & Trending Today

ASCO 2024: Belzutifan in Patients with Advanced Clear Cell Renal Cell Carcinoma: Subgroup Analysis of the Phase 2 LITESPARK-013 Study

Published: June 2, 2024

ASCO 2024, advanced clear cell renal cell carcinoma (ccRCC), Belzutifan, LITESPARK-013 Study, vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI).

Source: urotoday.com

Related Topics:

United StatesGeorgetown UniversityDistrict Of ColumbiaMichael AtkinsMichaelb AtkinsUniversity Of TorontoGeorgetown Lombardi Comprehensive Cancer CenterDepartment Of Medical OncologyDatabase ConsortiumGeorgetown University Medical CenterMerck Sharp DomeSociety Of Urologic OncologyInternational MetastaticAmerican Society Of Clinical OncologyClinical OncologyAnnual MeetingDeputy DirectorScholl ProfessorVice ChairMedical OncologyRashid SayyidUrologic OncologyClinical Fellow

Dr Atkins on the Rationale of Investigating Nivolumab/Ipilimumab in RCC

Published: April 7, 2023

Michael B. Atkins, MD, discusses the rationale for launching the phase 2 HCRN GU16-260 trial in patients with advanced renal cell carcinoma.

Source: onclive.com

Related Topics:

Michaelb AtkinsGeorgetown Lombardi Comprehensive Cancer CenterDepartment Of Medical OncologyGeorgetown University Medical CenterScholl ProfessorMedical OncologyClinical OncologyCancers SymposiumGeorgetown Lombardi Comprehensive Cancer CenteOnclive TvGenitourinary CancersRenal Cell Carcinoma